Abstract
Background: It is very important to evaluate the prognosis of multiple myeloma (MM) patients before starting treatment. Although haematopoietic status may have a significant impact on patient survival, it has not received sufficient attention in current clinical practice.
Methods: This was a retrospective study of 150 newly diagnosed MM patients treated in one hematonosis treatment centre from May 2013 to June 2016, all of whom received first-line treatment with a bortezomib-based regimen. The effects of haematopoietic factors, including haemoglobin levels (Hgb <100 g/L), mean corpuscular volume (MCV >99.1 fL), and platelet count (<150 × 10E9/L), on the prognosis of the patients were analysed. Each of the above factors was assigned a value of 1 to generate a haematopoietic score.
Results: According to the results, 59 (39.3%) patients had a score of 0, 43 (28.7%) had a score of 1, 29 (19.3%) had a score of 2, and 19 (12.7%) had a score of 3. The median PFS times were 43.1, 24.5, 32.6 and 14.2 months, respectively (P<0.001), and the median OS times were NR, 47.1 months, NR and 31.4 months, respectively (P<0.001). Multivariable analysis showed that the R-ISS stage (3 vs 1-2, HR, 1.4), haematopoietic score (3 vs 0-2, HR, 1.91) and plasma cell percentage (>30%, HR, 1.96) are independent prognostic predictors for PFS; age (≤65 years, HR, 0.54), the Durie-Salmon stage (3B vs 1-3a, HR, 2.96), haematopoietic score (3 vs 0-2, HR, 2.53) and the bone marrow plasma cell percentage (>30%, HR, 2.35) are independent prognostic predictors of OS.
Conclusion: This study suggests that the haematopoietic score can be used to evaluate the prognosis of newly treated MM patients in the era of new drugs.
Introduction
Multiple Myeloma (MM) is a heterogeneous cancer of the plasma cells. While survival has improved significantly with the introduction of proteasome inhibitors like bortezomib, predicting an individual patient's trajectory remains challenging. Current gold-standard staging systems, like the Revised International Staging System (R-ISS), rely on serum albumin, β2-microglobulin, LDH levels, and chromosomal analysis. However, these systems do not always fully account for the "haematopoietic status"—the functional health of the bone marrow. This study introduces a simple three-point "haematopoietic score" to improve prognostic accuracy using routine blood work.
Methods and Datasets
The researchers conducted a retrospective study of 150 newly diagnosed MM patients at the First Affiliated Hospital of Zhejiang University School of Medicine. All patients received a bortezomib-based regimen as their first-line treatment. The study utilized a clinical dataset including routine blood counts, bone marrow plasma cell percentages, and cytogenetic results.
The Haematopoietic Score (0–3) was calculated by assigning one point for each of the following clinical thresholds met at diagnosis:
- Hemoglobin (Hgb): < 100 g/L (Anemia)
- Mean Corpuscular Volume (MCV): > 99.1 fL (Macrocytosis)
- Platelet Count (Plt): < 150 × 10⁹/L (Thrombocytopenia)
Key Results
The impact of the haematopoietic score on patient outcomes was significant across both Progression-Free Survival (PFS) and Overall Survival (OS). Patients with a score of 0 had a median PFS of 43.1 months, compared to just 14.2 months for those with a score of 3. Similarly, the median OS for patients with a score of 0 was "Not Reached," while patients with a score of 3 had a median OS of only 31.4 months.
Multivariable analysis confirmed that the haematopoietic score is an independent predictor of survival. Even when accounting for R-ISS stage and age, a score of 3 carried a Hazard Ratio (HR) of 1.91 for PFS and 2.53 for OS compared to lower scores. Notably, MCV—a marker often overlooked in clinical practice—emerged as a significant independent predictor of poor outcomes when elevated.
Discussion and Conclusion
This study highlights the importance of the bone marrow "soil" in addition to the cancerous "seed." A high haematopoietic score suggests that the malignancy has significantly compromised the marrow's ability to produce healthy blood cells, leading to a poorer prognosis.
While the study is limited by its retrospective nature and sample size, the haematopoietic score offers a low-cost, easily accessible supplement to standard staging systems. Future work will focus on larger multi-center cohorts to validate these findings and explore the integration of this score with advanced cytogenetic data.
Summary updated